CO2019005101A2 - Anticuerpo biespecífico heterodimérico estructural de anticuerpo natural anti-pd-1/anti-her2 y método para preparar el mismo - Google Patents

Anticuerpo biespecífico heterodimérico estructural de anticuerpo natural anti-pd-1/anti-her2 y método para preparar el mismo

Info

Publication number
CO2019005101A2
CO2019005101A2 CONC2019/0005101A CO2019005101A CO2019005101A2 CO 2019005101 A2 CO2019005101 A2 CO 2019005101A2 CO 2019005101 A CO2019005101 A CO 2019005101A CO 2019005101 A2 CO2019005101 A2 CO 2019005101A2
Authority
CO
Colombia
Prior art keywords
antibody
preparing
heterodimeric bispecific
bispecific antibody
natural
Prior art date
Application number
CONC2019/0005101A
Other languages
English (en)
Inventor
Jiawang Liu
Nanmeng Song
Yaping Yang
Maengsup Kim
Original Assignee
Beijing Hanmi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Hanmi Pharmaceutical Co Ltd filed Critical Beijing Hanmi Pharmaceutical Co Ltd
Publication of CO2019005101A2 publication Critical patent/CO2019005101A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se proporcionan un anticuerpo biespecífico anti-PD-1/anti-HER2 de forma heterodimérica que tiene las características de una IgG natural y un método de preparación para el mismo. El anticuerpo se une a ambas moléculas diana simultáneamente, y se puede usar para tratar enfermedades complejas
CONC2019/0005101A 2016-11-18 2019-05-17 Anticuerpo biespecífico heterodimérico estructural de anticuerpo natural anti-pd-1/anti-her2 y método para preparar el mismo CO2019005101A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201611016435 2016-11-18
PCT/CN2017/111310 WO2018090950A1 (zh) 2016-11-18 2017-11-16 抗pd‐1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备

Publications (1)

Publication Number Publication Date
CO2019005101A2 true CO2019005101A2 (es) 2019-05-31

Family

ID=62146170

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0005101A CO2019005101A2 (es) 2016-11-18 2019-05-17 Anticuerpo biespecífico heterodimérico estructural de anticuerpo natural anti-pd-1/anti-her2 y método para preparar el mismo

Country Status (19)

Country Link
US (1) US11319378B2 (es)
EP (1) EP3533804A4 (es)
JP (1) JP7031810B2 (es)
KR (1) KR102247704B1 (es)
CN (1) CN109963876B (es)
AU (1) AU2017359813A1 (es)
BR (1) BR112019010051A2 (es)
CA (1) CA3043652A1 (es)
CL (1) CL2019001352A1 (es)
CO (1) CO2019005101A2 (es)
DO (1) DOP2019000124A (es)
EA (1) EA201990894A9 (es)
EC (1) ECSP19035482A (es)
MX (1) MX2019005858A (es)
PE (1) PE20191080A1 (es)
PH (1) PH12019501089A1 (es)
SG (1) SG10201913260VA (es)
TN (1) TN2019000161A1 (es)
WO (1) WO2018090950A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019003563A (es) * 2016-09-29 2019-08-12 Beijing Hanmi Pharmaceutical Co Ltd Construcciones de inmunoglobulina heterodimericas y metodos de preparacion de las mismas.
JP7031810B2 (ja) 2016-11-18 2022-03-08 ベイジン・ハンミ・ファーマシューティカル・カンパニー・リミテッド 抗ｐｄ－１／抗ｈｅｒ２天然抗体構造形態のヘテロダイマー系二重特異性抗体及びその製造方法
CN111615521A (zh) * 2017-12-04 2020-09-01 北京韩美药品有限公司 抗pd-l1/抗cd47天然抗体结构样异源二聚体形式双特异抗体及其制备
WO2019153200A1 (zh) * 2018-02-08 2019-08-15 北京韩美药品有限公司 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备
EP3878870A4 (en) * 2018-11-05 2022-08-03 Beijing Hanmi Pharmaceutical Co., Ltd. ANTI-TNFA/ANTI-IL-17A NATURAL ANTIBODY STRUCTURE-LIKE HETERODIMER FORM OF A BISPECIFIC ANTIBODY AND METHODS FOR ITS PRODUCTION
CN111196856A (zh) * 2018-11-19 2020-05-26 三生国健药业（上海）股份有限公司 抗her2/pd1双特异性抗体
CN111378045B (zh) * 2018-12-28 2022-08-02 长春金赛药业有限责任公司 二价双特异性抗体及其制备方法、编码基因、宿主细胞、组合物
EP4011390A4 (en) * 2019-08-07 2023-09-13 Innovent Biologics (Suzhou) Co., Ltd. PREPARATION WITH ANTI-PD-1/HER2 BISPECIFIC ANTIBODY AND METHOD FOR THE PRODUCTION AND USE THEREOF
CN111995685B (zh) * 2020-04-30 2022-03-08 中国科学院上海药物研究所 一种靶向her2和pd-1的双特异性抗体及其应用
WO2024061223A1 (zh) * 2022-09-20 2024-03-28 普米斯生物技术(珠海)有限公司 抗体及其在抗肿瘤中的应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9100352A (nl) 1991-02-27 1992-09-16 Hoogovens Groep Bv Werkwijze voor het vervaardigen van ijzerfolie door elektrodepositie.
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) * 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
SI1308455T1 (sl) * 1998-05-06 2006-08-31 Genentech Inc Sestavek, ki obsega protitelesa anti-HER2
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US20060074225A1 (en) 2004-09-14 2006-04-06 Xencor, Inc. Monomeric immunoglobulin Fc domains
KR101586617B1 (ko) 2007-06-18 2016-01-20 머크 샤프 앤 도메 비.브이. 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
DK2235064T3 (en) 2008-01-07 2016-01-11 Amgen Inc A process for the preparation of heterodimeric Fc molecules using electrostatic control effects
CA2759333A1 (en) 2009-04-22 2010-10-28 Merck Patent Gmbh Antibody fusion proteins with modified fcrn binding sites
ES2688978T3 (es) 2009-11-23 2018-11-07 Amgen Inc. Anticuerpo monomérico Fc
RS59589B1 (sr) 2010-11-05 2019-12-31 Zymeworks Inc Dizajniranje stabilnog heterodimernog antitela sa mutacijama u fc domenu
BR112013023918A2 (pt) 2011-03-25 2016-12-13 Glenmark Pharmaceuticals Sa imunoglobulina hetero-dimérica ou fragmento hetero-dimérico da mesma, método para produzir uma imunoglobulina hetero-dimérica ou fragmento hetero-dimérico da mesma, método para construir uma interface proteína-proteína de um domínio de uma proteína de múltiplos domínios e uso de um domínio doador de um primeiro e de um segundo membro de uma super-família de imunoglobulina de ocorrência natural
SI2699264T1 (en) 2011-04-20 2018-08-31 Medimmune Llc Antibodies and other molecules that bind B7-H1 and PD-1
EP2771364B1 (en) 2011-10-27 2019-05-22 Genmab A/S Production of heterodimeric proteins
CN104080811B (zh) 2011-11-04 2019-09-27 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
WO2014067011A1 (en) 2012-11-02 2014-05-08 Zymeworks Inc. Crystal structures of heterodimeric fc domains
NZ772318A (en) 2012-04-20 2023-06-30 Merus Nv Methods and means for the production of ig-like molecules
IN2015MN00139A (es) 2012-09-25 2015-10-16 Glenmark Pharmaceuticals Sa
CA2893562C (en) 2012-11-28 2023-09-12 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
CA2892585C (en) 2012-12-03 2022-07-05 Novimmune S.A. Anti-cd47 antibodies and methods of use thereof
CA2920113A1 (en) * 2013-08-20 2015-02-26 Merck Sharp & Dohme Corp. Treating cancer with a combination of a pd-1 antagonist and dinaciclib
CN112353943A (zh) 2013-12-17 2021-02-12 豪夫迈·罗氏有限公司 用pd-1轴结合拮抗剂和紫杉烷治疗癌症的方法
WO2015095412A1 (en) * 2013-12-19 2015-06-25 Zhong Wang Bispecific antibody with two single-domain antigen-binding fragments
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
HUE046661T2 (hu) 2014-08-15 2020-03-30 Merck Patent Gmbh SIRP-alfa immunglobulin fúziós proteinek
US20180265874A1 (en) 2014-10-10 2018-09-20 Global Biopharma, Inc. Methods for treating and/or preventing a tumor growth, invasion and/or metastasis
CN107530421B (zh) 2014-12-30 2021-07-20 细胞基因公司 抗cd47抗体及其用途
EP3245227A4 (en) * 2015-01-14 2018-07-25 Compass Therapeutics LLC Multispecific immunomodulatory antigen-binding constructs
WO2016170039A1 (en) 2015-04-23 2016-10-27 F. Hoffmann-La Roche Ag Combination therapy of antibody binding to angiopoietin 2 with antibody binding to programmed death 1 polypeptide
TW201709929A (zh) 2015-06-12 2017-03-16 宏觀基因股份有限公司 治療癌症的聯合療法
CN105111314B (zh) 2015-08-13 2019-01-08 成都百世博生物技术有限公司 一种新型融合蛋白、药物组合物及其制备方法和用途
CN105175545B (zh) 2015-10-20 2019-01-25 安徽瀚海博兴生物技术有限公司 一种抗vegf-抗pd-1双功能抗体及其应用
CN106883297B (zh) 2015-12-16 2019-12-13 苏州康宁杰瑞生物科技有限公司 基于ch3结构域的异二聚体分子、其制备方法及用途
US11459405B2 (en) 2015-12-28 2022-10-04 Massachusetts Institute Of Technology Bispecific antibodies having constant region mutations and uses therefor
WO2017167350A1 (en) 2016-03-30 2017-10-05 Horst Lindhofer Multispecific antibodies for use in the treatment of a neoplasm of the urinary tract
GB201611530D0 (en) 2016-07-01 2016-08-17 Alligator Bioscience Ab Novel polypeptides
MX2019003563A (es) 2016-09-29 2019-08-12 Beijing Hanmi Pharmaceutical Co Ltd Construcciones de inmunoglobulina heterodimericas y metodos de preparacion de las mismas.
CA3008775A1 (en) 2016-10-15 2018-04-19 Innovent Biologics (Suzhou) Co., Ltd Pd-1 antibodies
JP7031810B2 (ja) 2016-11-18 2022-03-08 ベイジン・ハンミ・ファーマシューティカル・カンパニー・リミテッド 抗ｐｄ－１／抗ｈｅｒ２天然抗体構造形態のヘテロダイマー系二重特異性抗体及びその製造方法
US11591409B2 (en) 2017-04-01 2023-02-28 Beijing Hanmi Pharm. Co., Ltd. Anti-PD-L1/anti-PD-1 natural antibody structure-like heterodimeric bispecific antibody and preparation thereof
AR112603A1 (es) 2017-07-10 2019-11-20 Lilly Co Eli Anticuerpos biespecíficos inhibidores de punto de control
CN107325184A (zh) 2017-08-08 2017-11-07 安徽大学 一种靶向egfr和her2的双特异性抗体及其应用
EA039662B1 (ru) 2017-10-03 2022-02-24 Закрытое Акционерное Общество "Биокад" Антитела, специфичные к cd47 и pd-l1
CN111615521A (zh) 2017-12-04 2020-09-01 北京韩美药品有限公司 抗pd-l1/抗cd47天然抗体结构样异源二聚体形式双特异抗体及其制备
WO2019153200A1 (zh) 2018-02-08 2019-08-15 北京韩美药品有限公司 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备
CN111712522A (zh) 2018-02-11 2020-09-25 北京韩美药品有限公司 抗pd-1/抗vegf天然抗体结构样异源二聚体形式双特异抗体及其制备

Also Published As

Publication number Publication date
KR102247704B1 (ko) 2021-05-03
AU2017359813A1 (en) 2019-05-30
KR20190065375A (ko) 2019-06-11
EP3533804A4 (en) 2020-06-17
PH12019501089A1 (en) 2020-03-02
WO2018090950A1 (zh) 2018-05-24
CN109963876A (zh) 2019-07-02
MX2019005858A (es) 2019-08-12
ECSP19035482A (es) 2019-05-31
EP3533804A1 (en) 2019-09-04
SG10201913260VA (en) 2020-03-30
EA201990894A9 (ru) 2019-11-27
DOP2019000124A (es) 2019-11-15
BR112019010051A2 (pt) 2019-09-03
CL2019001352A1 (es) 2019-08-02
JP7031810B2 (ja) 2022-03-08
CA3043652A1 (en) 2018-05-24
PE20191080A1 (es) 2019-08-20
TN2019000161A1 (en) 2020-10-05
JP2020510407A (ja) 2020-04-09
US20190367633A1 (en) 2019-12-05
EA201990894A1 (ru) 2019-09-30
CN109963876B (zh) 2023-11-14
US11319378B2 (en) 2022-05-03

Similar Documents

Publication Publication Date Title
CO2019005101A2 (es) Anticuerpo biespecífico heterodimérico estructural de anticuerpo natural anti-pd-1/anti-her2 y método para preparar el mismo
DOP2018000259A (es) Proteínas de unión biespecíficas que se unen a una proteína inmunomoduladora y a un antígeno tumoral
CR20180161A (es) Anticuerpos biespecíficos para pd1 y tim3
PH12019500655A1 (en) Heterodimeric immunoglobulin constructs and preparation methods thereof
CO2019012210A2 (es) Anticuerpos anti-trem2 y métodos para utilizarlos
AR113342A1 (es) Anticuerpos específicos cd47 / pd-l1
CO2017012553A2 (es) Moléculas de unión a lag-3
CL2016003346A1 (es) Anticuerpos anti-tau humanizados
PE20201341A1 (es) Anticuerpos de union a gprc5d
PE20171103A1 (es) Anticuerpos heterodimericos que se unen a cd3 y cd38
CO2017007123A2 (es) Anticuerpos biespecíficos contra calicreína y factor xii del plasma
CR20190009A (es) Anticuerpos anti-pd-1, un método de producción y un método para su uso.
EA201891709A1 (ru) Антигенсвязывающие белки, связывающие pd-l1
CU24427B1 (es) Moléculas de anticuerpo que se unen a tim-3
PE20151289A1 (es) Anticuerpos que se unen al tl1a y sus usos
CO2019011458A2 (es) Anticuerpo monoclonal para pd-l1
CO2017010631A2 (es) Método para purificación de proteína
AR114102A1 (es) Anticuerpo biespecífico heterodimérico estructural natural anti-pd-1 / anti-her2 y método para su preparación
AR118763A1 (es) Anticuerpo monoclonal que se une específicamente a gitr
CL2019002735A1 (es) Anticuerpos que se unen a steap-1.
PE20191743A1 (es) Anticuerpos biespecificos anti-pd-l1-anti-tim3
ECSP20024551A (es) ANTICUERPO MONOCLONAL PARA IL-5Ra
AR102872A1 (es) Anticuerpos anti-pd-1 y sus métodos de uso
AR106198A1 (es) Anticuerpos biespecíficos para la proteína de muerte celular programada 1 (pd1) y para la proteína humana que pertenece a la superfamilia de las inmunoglobulinas (tim3)
EA202091181A3 (ru) Антитела и способы их применения